Association of Glucose-6-Phosphate Dehydrogenase Deficiency With Outcomes in US Veterans With COVID-19
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.5626 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von Sarah H Elsea und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. Hauptthemen laut MEDLINE: COVID-19, Veterans, Glucosephosphate Dehydrogenase Deficiency. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Importance The underlying biological risk factors for severe outcome due to SAR-CoV-2 infection are not well defined.
Objective
To determine the association between glucose-6-phosphate dehydrogenase (G6PD) deficiency and severity of COVID-19. Design, Setting, and Participants This retrospective cohort study included analysis of 24 700 veterans with G6PD enzyme testing prior to January 1, 2020, obtained through the US Veterans Health Administration national databases. These veterans were cross-referenced with the Veterans Administration COVID-19 Shared Data Resource for SARS-CoV-2 testing from February 15, 2020, to January 1, 2021. The final study population consisted of 4811 veterans who tested positive for SARS-CoV-2. Statistical analysis was performed from June to December 2021. Exposures G6PD deficiency. Main Outcomes and Measures COVID-19 severe illness, as defined by the Centers for Disease Control and Prevention: hospitalization, need for mechanical ventilation and/or intensive care unit admission, or in-hospital mortality after a positive SARS-CoV-2 test.
Results
Among 4811 veterans in the Veterans Health Administration who had historical G6PD enzyme activity test results and SARS-CoV-2 positivity included in this study, 3868 (80.4%) were male, 1553 (32.3%) were Black, and 1855 (39%) were White; 1228 (25.5%) were 65 years or older and 3583 (74.5%) were younger than 65 years. There were no significant differences in age, body mass index, or Charlson Comorbidity Index were present between the veterans with G6PD deficiency and without G6PD deficiency. Among these veterans with SARS-CoV-2 infection, G6PD deficiency was more prevalent in Black male veterans (309 of 454 [68.1%]) compared with other racial and ethnic groups. Black male veterans less than 65 years of age with G6PD deficiency had approximately 1.5-fold increased likelihood of developing severe outcomes from SARS-CoV-2 infection compared with Black male veterans without G6PD deficiency (OR, 1.47; 95% CI, 1.03-2.09). In the small subset of White male veterans with G6PD deficiency, we observed an approximately 3.6-fold increased likelihood of developing severe outcomes from SARS-CoV-2 infection compared with White male veterans aged 65 years or older without G6PD deficiency (OR, 3.58; 95% CI, 1.64-7.80). This difference between veterans with and without G6PD deficiency was not observed in younger White male veterans or older Black male veterans, nor in smaller subsets of other male veterans or in female veterans of any age. Conclusions and Relevance In this cohort study of COVID-19–positive veterans, Black male veterans less than 65 years of age and White male veterans 65 years of age or older with G6PD deficiency had an increased likelihood of developing severe COVID-19 compared with veterans without G6PD deficiency. These data indicate a need to consider the potential for G6PD deficiency prior to treatment of patients with SARS-CoV-2 infection as part of clinical strategies to mitigate severe outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for Translational Research on Inflammatory Diseases (CTRID), Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas.
- Big Data Scientist Training Enhancement Program (BD-STEP), VA Office of Research and Development, Salt Lake City, Utah.
- VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah.
- Department of Internal Medicine, School of Medicine, University of Utah, Salt Lake City.
- National Neurology Program, Specialty Care Program Office, Veterans Health Administration, Washington, DC.
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
Zitieren
APA
Elsea, S. H., Razjouyan, J., Lee, K. M., Lynch, J. A., Martini, S., & Pandit, L. M. (2023). Association of Glucose-6-Phosphate Dehydrogenase Deficiency With Outcomes in US Veterans With COVID-19. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.5626
Vancouver
Elsea SH, Razjouyan J, Lee KM, Lynch JA, Martini S, Pandit LM. Association of Glucose-6-Phosphate Dehydrogenase Deficiency With Outcomes in US Veterans With COVID-19. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.5626
BibTeX
@article{Elsea2023,
author = {Elsea, Sarah H and Razjouyan, Javad and Lee, Kyung Min and Lynch, Julie A and Martini, Sharyl and Pandit, Lavannya M},
title = {Association of Glucose-6-Phosphate Dehydrogenase Deficiency With Outcomes in US Veterans With COVID-19},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.5626}
}
EUVIMED